Implementing Cabenuva in Arkansas HIV Programs
Implementing Long-Acting Cabotegravir + Rilpivirine in Arkansas Programs Utilizing Out-patient Clinics Versus In-home Visits
Sponsor: University of Arkansas
Terminated
Insufficient enrollment.
Other terminated trials from University of Arkansas
Other HIV-1-infection trials with similar outcome
This NA trial investigates HIV-1-infection and Medication Adherence and is currently terminated or withdrawn. University of Arkansas leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Oct 2024 — Present [monthly]
Terminated NA
-
Sep 2024 — Oct 2024 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Feb 2024 — Jul 2024 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Oct 2023 — Feb 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Nov 2022 — Oct 2023 [monthly]
Recruiting NA
-
Apr 2022 — Nov 2022 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting NA
Phase: EARLY_PHASE1 → NA
-
Dec 2021 — Mar 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Arkansas
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .